Quinacrine

Quinacrine

SCHEMBL1817364

CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12.CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 1.00
TP53 P04637 3/20 1.00
CYP3A4 P08684 3/20 1.00
CASP1 P29466 3/20 1.00
CASP7 P55210 3/20 1.00
HBB P68871 3/20 1.00
HSD17B10 Q99714 3/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
TSHR P16473 2/20 1.00
BRCA1 P38398 2/20 1.00
HIF1A Q16665 2/20 1.00
NPC1 O15118 1/20 1.00
PRNP P04156 1/20 1.00
CHRM2 P08172 1/20 1.00
CHRM4 P08173 1/20 1.00
ABCB1 P08183 1/20 1.00
HTR1A P08908 1/20 1.00
CHRM5 P08912 1/20 1.00
ADRA2A P08913 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinacrine SCHEMBL29363141 1.00 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL19225 1.00 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL20205 1.00 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL29717736 1.00 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL17704776 1.00 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL33693 0.99 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL30153780 0.99 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL15061349 0.99 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL162379 0.99 USP2 (1.00) USP2TP53CYP3A4CASP1CASP7
Quinacrine SCHEMBL28651594 0.99 USP2 (0.98) USP2TP53CYP3A4CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630083-A1 DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF The Regents of The University of Michigan (US) 2020-04-08 EP disclosed
WO-2020057225-A1 ANTI-PD-L1 ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 苏州泓迅生物科技股份有限公司 2020-03-26 WO disclosed
WO-2019040724-A1 SMALL MOLECULE INHIBITORS OF MYC AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-02-28 WO disclosed
EP-3426249-A1 SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY The Regents of The University of Michigan (US) 2019-01-16 EP disclosed
WO-2018217873-A1 DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-11-29 WO disclosed
WO-2018081719-A1 SMALL MOLECULE INHIBITORS OF NEK2 AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2018-05-03 WO disclosed
EP-3285583-A1 SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF The Regents of The University of Michigan (US) 2018-02-28 EP disclosed
EP-3233085-A2 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K The Regents of The University of Michigan (US) 2017-10-25 EP disclosed
WO-2017165663-A1 BIOMARKERS FOR CANCER ASSOCIATED WITH HEDGEHOG PATHWAY ACTIVITY AND RELATED USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2017-09-28 WO disclosed
WO-2017155991-A1 SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-09-14 WO disclosed
WO-2014037412-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE PHARNEXT (FR) 2014-03-13 WO disclosed
EP-2560631-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS Pharnext (FR) 2013-02-27 EP disclosed
EP-2496226-A1 NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE Pharnext (FR) 2012-09-12 EP disclosed
WO-2012117076-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS PHARNEXT (FR) 2012-09-07 WO disclosed
WO-2012117073-A2 NEW COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS PHARNEXT (FR) 2012-09-07 WO disclosed
WO-2011102999-A2 SPINK1 TARGETED THERAPY THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-08-25 WO disclosed
WO-2011054759-A1 NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE PHARNEXT (FR) 2011-05-12 WO disclosed
EP-0831856-A2 USE OF HYDROXYETHYL STARCH TO PREVENT POST SURGICAL ADHESION AND AS AN INTRACAVITY CARRIER DEVICE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1998-04-01 EP disclosed
WO-1996040168-A2 USE OF HYDROXYETHYL STARCH TO PREVENT POST SURGICAL ADHESION AND AS AN INTRACAVITY CARRIER DEVICE UNIVERSITY OF SOUTHERN CALIFORNIA (US) 1996-12-19 WO disclosed
US-4820714-A QUINACRINE OR DIMETHYL D,1-2,3-DISTEAROYLOXYPROPYL-2*-HYDROXYETHYL AMMONIUM ACETATE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1989-04-11 US disclosed